Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Crizanlizumab Cohort | Patients with sickle cell disease (SCD) who had received at least one dose of crizanlizumab between 2019 and 2022. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Age at Index Date | Index date was defined as the date of the first crizanlizumab infusion | Day 1 of Year 2 |
| Gender at Index Date | Index date was defined as the date of the first crizanlizumab infusion | Day 1 of Year 2 |
| Race | Day 1 of Year 2 | |
| Ethnicity | Day 1 of Year 2 | |
| Insurance Type at Index Date | Index date was defined as the date of the first crizanlizumab infusion | Day 1 of Year 2 |
| Number of Patients Categorized by Comorbidity | Baseline | |
| Number of Patients who Received Long-acting Opioid Medication Before Starting Crizanlizumab | Baseline | |
| Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy Before Starting Crizanlizumab Categorized by Duration of Therapy | Red blood cell transfusion therapy time intervals:
| Baseline |
| Number of Patients who Received Chronic Red Blood Cell Transfusion Therapy After Starting Crizanlizumab Categorized by Duration of Therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Doses Received by Patients Who Continued and Discontinued Crizanlizumab Treatment | 1 year | |
| Number of SCD-related Hospitalizations and Emergency Department Visits Pre- and Post-index Date | Index date was defined as the date of the first crizanlizumab infusion. |
Not provided
Inclusion criteria
Exclusion criteria None identified.
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Red blood cell transfusion therapy time intervals:
| Up to 1 year |
| Number of Patients by Type of Disease Modifying Therapy (DMT) Received Pre- and Post-index Date | Index date was defined as the date of the first crizanlizumab infusion. DMTs included:
| Up to 2 years |
| Up to 2 years |
| Length of Stay of SCD-related Hospitalization Visits Pre- and Post-index Date | Index date was defined as the date of the first crizanlizumab infusion. | Up to 2 years |
| D006425 |
| Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |